Top-down Infliximab Study in Kids With Crohn's Disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Mar 2024 Status changed from active, no longer recruiting to completed.
11 Oct 2022 Results assessing whether combination therapy has pharmacokinetic benefits over proactive therapeutic drug monitoring mono therapy Infliximab, comparing drug exposure expressed as area under concentration curve (AUC), trough concentrations (TL) and IFX clearance (CL) between combo and proactive therapeutic drug monitoring mono Infliximab treated patients, presented at the 30th United European Gastroenterology Week.
01 Aug 2022 Results (n=47) assessing the proportion of patients in which EEN or corticosteroids induced remission and maintained remission on azathioprine monotherapy, published in the European Journal of Pediatrics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com